Meeting
2016 ASCO Annual Meeting
Comparing the cost-effectiveness of immunotherapy strategies in BRAF wild-type advanced melanoma.
Authors
Simon B. Zeichner
Winship Cancer Institute at Emory University, Atlanta, GA
Simon B. Zeichner , Christine Kohn , Qiushi Chen , Daniel A. Goldstein , Alberto J. Montero , Christopher Flowers
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality of Care
Track
Health Services Research and Quality of Care
Sub Track
Value/Cost of Care
Citation
J Clin Oncol 34, 2016 (suppl; abstr 6607)
DOI
10.1200/JCO.2016.34.15_suppl.6607
Abstract #
6607
Poster Bd #
92
Abstract Disclosures
Similar Posters
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Outcomes of immunotherapy in advanced melanoma in relation to age.
First Author: Krishna Prasad Joshi
Poster
2024 ASCO Annual Meeting
Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma.
First Author: Paul Lorigan
Poster
2023 ASCO Genitourinary Cancers Symposium
Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A).
First Author: Michael B. Atkins
Poster
2022 ASCO Annual Meeting
Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.
First Author: F. Stephen Hodi